Amicus Therapeutics, Inc. (NASDAQ:FOLD) Insider Trading Activity – CEO Sold 14,500 shares of Stock

ME Staff
-
0

Insider Trading Activity For Amicus Therapeutics, Inc. (NASDAQ:FOLD)

John F Crowley , CEO of Amicus Therapeutics, Inc. (NASDAQ:FOLD) reportedly Sold 14,500 shares of the company’s stock at an average price of 8.01 for a total transaction amount of $116,145.00 SEC Form

Insider Trading History For Amicus Therapeutics, Inc. (NASDAQ:FOLD)

  • On 11/13/2012 Joan Winterbottom, SVP, bought 1,665 with an average share price of $4.54 per share and the total transaction amounting to $7,559.10.
  • On 3/15/2013 Sol J Barer, Director, bought 25,000 with an average share price of $3.40 per share and the total transaction amounting to $85,000.00.
  • On 11/20/2013 Plc Glaxosmithkline, major shareholder, bought 1,500,000 with an average share price of $2.00 per share and the total transaction amounting to $3,000,000.00.
  • On 6/30/2014 Perceptive Advisors Llc, Major Shareholder, bought 4,000,000 with an average share price of $3.50 per share and the total transaction amounting to $14,000,000.00.
  • On 8/20/2014 Enrique Dilone, VP, sold 12,810 with an average share price of $5.40 per share and the total transaction amounting to $69,174.00.
  • On 8/20/2014 Bradley L Campbell, COO, sold 18,750 with an average share price of $5.40 per share and the total transaction amounting to $101,250.00.
  • On 8/25/2014 Jayne Gershkowitz, VP, sold 5,000 with an average share price of $6.00 per share and the total transaction amounting to $30,000.00.

    • Analyst Ratings History For Amicus Therapeutics, Inc. (NASDAQ:FOLD)

    • On 2/8/2018 Leerink Swann Boost Price Target of rating Outperform to Outperform with a price target of $20.00 to $24.00
    • On 10/12/2018 Chardan Capital Reiterated Rating Hold with a price target of $15.00
    • On 12/17/2018 Guggenheim Initiated Coverage of rating Buy with a price target of $18.00
    • On 1/16/2019 Citigroup Upgraded rating Neutral to Buy with a price target of $12.59
    • On 4/5/2019 Janney Montgomery Scott Initiated Coverage of rating Buy to Buy with a price target of $13.91
    • On 4/22/2019 Robert W. Baird Set Price Target of rating Buy with a price target of $20.00
    • On 6/5/2019 Cantor Fitzgerald Reiterated Rating Overweight to Overweight with a price target of $20.00 to $19.00

    Recent Trading Activity for Amicus Therapeutics, Inc. (NASDAQ:FOLD)
    Shares of Amicus Therapeutics, Inc. closed the previous trading session at with 2560400 shares trading hands.